 SAN FRANCISCO, April 19, 2021 PRNewswire -- Schubert Jonckheer Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Geron Corporation NASDAQ: GERN relating to possible false statements to investors and insider trading by an officer and a director. A securities class action against the company in the U.S. District Court for the Northern District of California recently survived a motion to dismiss allegations that between March 19 and September 26, 2018, Geron and its CEO made false and misleading statements about the effectiveness of the drug imetelstat, which was then under study for the treatment of myelofibrosis, a rare blood cancer. 